AVTX Covered Call Strategy
AVTX (Avalo Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX (Avalo Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $224.2M, a beta of 0.79 versus the broader market, a 52-week range of 3.431-24.27, average daily share volume of 1.3M, a public-listing history dating back to 2015, approximately 23 full-time employees. These structural characteristics shape how AVTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.79 places AVTX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on AVTX?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current AVTX snapshot
As of May 15, 2026, spot at $17.52, ATM IV 82.50%, IV rank 14.28%, expected move 23.65%. The covered call on AVTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on AVTX specifically: AVTX IV at 82.50% is on the cheap side of its 1-year range, which means a premium-selling AVTX covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 23.65% (roughly $4.14 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AVTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on AVTX should anchor to the underlying notional of $17.52 per share and to the trader's directional view on AVTX stock.
AVTX covered call setup
The AVTX covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AVTX near $17.52, the first option leg uses a $18.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AVTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AVTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $17.52 | long |
| Sell 1 | Call | $18.40 | N/A |
AVTX covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
AVTX covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on AVTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on AVTX
Covered calls on AVTX are an income strategy run on existing AVTX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
AVTX thesis for this covered call
The market-implied 1-standard-deviation range for AVTX extends from approximately $13.38 on the downside to $21.66 on the upside. A AVTX covered call collects premium on an existing long AVTX position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether AVTX will breach that level within the expiration window. Current AVTX IV rank near 14.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AVTX at 82.50%. As a Healthcare name, AVTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AVTX-specific events.
AVTX covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AVTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AVTX alongside the broader basket even when AVTX-specific fundamentals are unchanged. Short-premium structures like a covered call on AVTX carry tail risk when realized volatility exceeds the implied move; review historical AVTX earnings reactions and macro stress periods before sizing. Always rebuild the position from current AVTX chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on AVTX?
- A covered call on AVTX is the covered call strategy applied to AVTX (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With AVTX stock trading near $17.52, the strikes shown on this page are snapped to the nearest listed AVTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AVTX covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the AVTX covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 82.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AVTX covered call?
- The breakeven for the AVTX covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AVTX market-implied 1-standard-deviation expected move is approximately 23.65%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on AVTX?
- Covered calls on AVTX are an income strategy run on existing AVTX stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current AVTX implied volatility affect this covered call?
- AVTX ATM IV is at 82.50% with IV rank near 14.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.